Benchtop Cell Sorter Validated in Biosafety Containment Setting
|
By LabMedica International staff writers Posted on 27 Dec 2021 |

Image: The MACSQuant Tyto Cell Sorter can be used safely in at BSL-3 laboratory facilities (Photo courtesy of Miltenyi Biotec)
Fluorescent-activated cell sorting (FACS) is often the most appropriate technique to obtain pure populations of a cell type of interest for downstream analysis. The ability to sort pure populations of immune cells is a critical tool for immunologists.
Aerosol droplets can be generated during the sort, which poses a biosafety risk when working with samples containing risk group 3 pathogens such as Francisella tularensis, Mycobacterium tuberculosis, Yersinia pestis, and severe acute respiratory syndrome coronavirus 2.
Pulmonary pathogen specialists at the Rocky Mountain Laboratories (Hamilton, MT, USA) performed aerosol testing as part of the biosafety evaluation of the MACSQuant Tyto (Miltenyi Biotec, Bergisch Gladbach, Germany) a completely closed, cartridge-based cell sorter. They also established quality control procedures to routinely evaluate instrument performance. Aerosol testing was performed on FACSAria II (BD Biosciences, San Diego, CA, USA) with the Aerosol Management System disabled as a positive control for aerosol generation.
The scientists reported that before usage of the Tyto on the benchtop to sort cells at BSL-3, it was necessary to empirically determine if aerosols were generated during the cell sort procedure. They utilized a novel method using internally fluorescent 1.0 μm beads to perform aerosol testing on the Tyto. These beads were uniform in size and intensely fluorescent in the fluorescein isothiocyanate (FITC) channel.
As a positive control, they detected aerosols generated by the in-house FACSAria II when the Aerosol Management System was disabled, and the flow stream disrupted. As expected, beads were detected on the coverslip after only a 30-second exposure. The MACSQuant Tyto did not produce aerosols as part of the sort procedure. The scientists established a purity of >96%, depletion yield of >80%, and sort efficiency of >85% as benchmarks that must be met during quality control testing.
The authors concluded that they utilized the Tyto cell sorter in their BSL-3 laboratory. This instrument not only has a small footprint but most importantly does not generate aerosols during the sort procedure. The use of this technology will improve current immunological studies in containment laboratories by allowing a greater number of scientific groups to isolate cell types involved in the immune response to high-consequence pathogens for downstream applications. The study was published on November 24, 2021 in the journal Applied Biosafety.
Related Links:
Rocky Mountain Laboratories
Miltenyi Biotec
BD Biosciences
Aerosol droplets can be generated during the sort, which poses a biosafety risk when working with samples containing risk group 3 pathogens such as Francisella tularensis, Mycobacterium tuberculosis, Yersinia pestis, and severe acute respiratory syndrome coronavirus 2.
Pulmonary pathogen specialists at the Rocky Mountain Laboratories (Hamilton, MT, USA) performed aerosol testing as part of the biosafety evaluation of the MACSQuant Tyto (Miltenyi Biotec, Bergisch Gladbach, Germany) a completely closed, cartridge-based cell sorter. They also established quality control procedures to routinely evaluate instrument performance. Aerosol testing was performed on FACSAria II (BD Biosciences, San Diego, CA, USA) with the Aerosol Management System disabled as a positive control for aerosol generation.
The scientists reported that before usage of the Tyto on the benchtop to sort cells at BSL-3, it was necessary to empirically determine if aerosols were generated during the cell sort procedure. They utilized a novel method using internally fluorescent 1.0 μm beads to perform aerosol testing on the Tyto. These beads were uniform in size and intensely fluorescent in the fluorescein isothiocyanate (FITC) channel.
As a positive control, they detected aerosols generated by the in-house FACSAria II when the Aerosol Management System was disabled, and the flow stream disrupted. As expected, beads were detected on the coverslip after only a 30-second exposure. The MACSQuant Tyto did not produce aerosols as part of the sort procedure. The scientists established a purity of >96%, depletion yield of >80%, and sort efficiency of >85% as benchmarks that must be met during quality control testing.
The authors concluded that they utilized the Tyto cell sorter in their BSL-3 laboratory. This instrument not only has a small footprint but most importantly does not generate aerosols during the sort procedure. The use of this technology will improve current immunological studies in containment laboratories by allowing a greater number of scientific groups to isolate cell types involved in the immune response to high-consequence pathogens for downstream applications. The study was published on November 24, 2021 in the journal Applied Biosafety.
Related Links:
Rocky Mountain Laboratories
Miltenyi Biotec
BD Biosciences
Latest Technology News
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more








